Recent news on Soriatane

Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ...  -  Apr 23, 2007
PR Newswire (press release),0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; Soriatane(R) (acitretin) capsules;

Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ...  -  Apr 23, 2007
PharmaLive.com (press release),0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; Soriatane(R) (acitretin) capsules;

Stiefel Laboratories, Inc. Donates First Dermatology Ward in ...  -  Feb 2, 2007
Drug Newswire (press release),Some of the best-known brands include Sarna(R), Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R) Creamy Wash, Oilatum(R), Soriatane(R),

Stiefel Laboratories, Inc. Completes Acquisition of Connetics ...  -  Dec 29, 2006
PharmaLive.com (press release),Some of the best-known brands include Sarna(R), Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R)Creamy Wash, Oilatum(R), Soriatane(R), Evoclin(R),

Stiefel Laboratories, Inc. Completes Acquisition of Connetics ...  -  Dec 28, 2006
Yahoo! News (press release)Some of the best-known brands include Sarna®, Duac® Topical Gel, MimyX(TM) Cream, Olux®, Brevoxyl®Creamy Wash, Oilatum®, Soriatane®, Evoclin®, Verdeso(TM)

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Genetic Engineering News (press release),The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin)

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Business Wire (press release),The Company's marketed products are OLUX ® (clobetasol propionate) Foam, 0.05%; Luxíq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin)

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Genetic Engineering News (press release),The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin)

Connetics Announces Results of Special Stockholders Meeting  -  Dec 20, 2006
Business Wire (press release),The Company's marketed products are OLUX ® (clobetasol propionate) Foam, 0.05%; Luxíq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin)

Stiefel Laboratories Rated 'B+'; Secured Debt Also Rated  -  Dec 6, 2006
PharmaLive.com (press release),The company will have a diverse product portfolio, with its top three products--Duac, Soriatane, and Olux--collectively accounting for only 34% of total

Connetics Reports Third Quarter Financial Results  Nov 8, 2006
Third quarter 2006 product revenues include Soriatane® sales of $10.4 million, OLUX® sales of $4.3 million, Evoclin® sales of $2.3 million and Luxíq ... -Business Wire (press release), Connetics Corporation to Merge into Stiefel Laboratories  Oct 24, 2006
The Company's commercial products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin ... -Drug Newswire (press release), Stiefel to purchase Connetics  Oct 24, 2006
Cream with Sunscreens. Connetics sells Olux Foam, Luxiq Foam, Soriatane capsules, Evoclin Foam and Verdeso Foam. The company's development ... -San Antonio Business Journal, Connetics Corporation to Merge into Stiefel Laboratories  Oct 23, 2006
The Company's commercial products are OLUX® (clobetasol propionate) Foam, 0.05%; Luxiq® (betamethasone valerate) Foam, 0.12%; Soriatane® (acitretin) capsules ... -Yahoo! News (press release) Connetics Corporation and Stiefel Laboratories, Inc. Sign ...  Oct 23, 2006
Company's commercial products are OLUX ® (clobetasol propionate) Foam, 0.05%; Luxiq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin) capsules ... -Business Wire (press release), Debate again shadows Accutane  24 Sep 2006
...approved for epilepsy that are now widely prescribed mostly off-label for depression and other psychiatric problems; the psoriasis drugs Soriatane and Tegison ... -Fort Wayne Journal Gazette

FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to ...  Sep 20, 2006
The Company's commercial products are OLUX (clobetasol propionate) Foam, 0.05%; Luxiq (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) capsules ... -PharmaLive.com

Connetics Reports Positive Results From Second Phase III Clinical ...  Aug 28, 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin ... -Genetic Engineering News

Stiefel Laboratories Rated 'B+'; Secured Debt Also Rated  -  Dec 6, 2006
PharmaLive.com (press release),The company will have a diverse product portfolio, with its top three products--Duac, Soriatane, and Olux--collectively accounting for only 34% of total

Connetics Announces Special Meeting of Stockholders to Approve ...  -  Nov 17, 2006
Business Wire (press release),The Company's marketed products are OLUX ® (clobetasol propionate) Foam, 0.05%; Luxíq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin)

Connetics Reports Positive Results From Second Phase III Clinical ...  29 Aug 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin ... -PipelineReview.com

Connetics Reports Second Quarter Financial Results  Aug 14, 2006
Second quarter 2006 revenues include Soriatane(R) sales of $16.3 million, OLUX(R) sales of $12.2 million, Evoclin(R) sales of $9.3 million and Luxiq(R) sales ... -Business Wire

Connetics Reports New Option Grants Under Nasdaq Marketplace Rule ...  Aug 7, 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin ... -Business Wire

Connetics Announces Extension and Changes in Terms of Convertible ...  Jul 19, 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin ... -Business Wire



Psoriasis Treatments – What Are the Options?  May 2, 2006
UVB light treatment is also used with Soriatane, a drug derived from Vitamin A. Although it does not have many side effects in itself, it can cause birth ... - The Open Press

Connetics Reports Preliminary Results for First Quarter 2006 ...  May 3, 2006
Total revenues for the first quarter of 2006 were $47.7 million, including Soriatane(R) sales of $19.0 million, OLUX(R) sales of $14.1 million, Evoclin(R ... - PharmaLive.com

Connetics Names Sunil Patel Vice President, Corporate Development ...  May 9, 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin ... - PharmaLive.com





Connetics Files Citizen Petition for Soriatane With the FDA ...  Apr 3, 2006
...the filing of a Citizen Petition with the US Food and Drug Administration (FDA) to request that any generic products that reference Soriatane(R) (acitretin ... - Genetic Engineering News

Connetics Says It Has Filed Citizen Petition For Soriatane With ...  Apr 3, 2006
...announced the filing of a Citizen Petition with the US Food and Drug Administration to request that any generic products that reference Soriatane meet several ... - Trading Markets

Connetics Provides Information on Securities and Exchange ...  Apr 7, 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin ... - PharmaLive.com



Connetics says lower dosage of psoriasis drug found effective  Mar 3, 2006
March 3 (Reuters) - Connetics Corp. (CNCT.O: Quote, Profile, Research) on Friday said it found lower dosages of its psoriasis drug Soriatane to be as effective ... - Reuters

Connetics Names Freddie Park Vice President, Intellectual Property ...  Feb 6, 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin ... - Genetic Engineering News,

March of Dimes Applauds FDA Monitoring Program  09 Feb 2006
The organization's comments came in a national policy statement on retinoid drugs such as Accutane and the psoriasis medication Soriatane (acitretin). ... - PR Newswire

Connetics Names Freddie Park Vice President, Intellectual Property ...  Feb 6, 2006
R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin ... - Genetic Engineering News

Connetics Reports Fourth Quarter Revenues of $41.3 Million and EPS ...  Jan 31, 2006
Fourth quarter 2005 product revenues included OLUX(R) sales of $14.7 million, Soriatane(R) sales of $13.6 million, Evoclin(TM) sales of $6.9 million and Luxiq(R ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional